Published on 7 Oct 2024 on GuruFocus.com · via Yahoo Finance
Evolent Health Inc (EVH) Q2 2024 Earnings Call Highlights: Strong Revenue Growth...
Revenue: $647.1 million for Q2 2024, representing a 37.9% year-over-year growth.Adjusted EBITDA: $52 million for Q2 2024, towards the lower part of the expected range.Cash Position: $101 million in cash and equivalents at the end of Q2 2024.Adjusted Gross Margin: 16.7% for Q2 2024, an increase of about 30 basis points from Q1 2024.Specialty Tech and Services Revenue: $81.5 million, down $7.5 million sequentially.SG&A Expenses: $56.1 million, down $13.7 million year-over-year.Cash Flow from Operations: $26.3 million year-to-date, including $22.2 million of earn-out payment.New Revenue Agreements: Over $70 million in new annualized revenue bookings from four agreements.Full Year Revenue Guidance: Raised to $2.56 billion to $2.6 billion.Full Year Adjusted EBITDA Guidance: Updated to $230 million to $245 million.
Warning! GuruFocus has detected 3 Warning Signs with EVH.